Core Insights - Agilent Technologies reported second-quarter fiscal 2025 earnings of 1.31pershare,exceedingtheZacksConsensusEstimateby3.971.67 billion, surpassing the Zacks Consensus Estimate by 2.64%, with a reported increase of 6% and a core increase of 5.3% compared to the previous year [1] Revenue Growth Drivers - Growth was primarily driven by sustained improvements in Pharmaceuticals and increased demand across Diagnostics and Clinical, Food, and Environmental and Forensics markets [2] Segment Performance - Life Sciences and Diagnostics Markets Group (LDG): Generated 654million,accountingfor39.2713 million, representing 42.7% of total revenues, with a 7% increase on a reported basis and a 9% increase on a core basis, led by double-digit growth in automation and consumables [4] - Applied Markets Group (AMG): Revenues decreased 1% year over year to 301million,accountingfor18109 million, down 3.5% year over year, while SG&A expenses rose slightly to 374million,markinga2.21.49 billion, up from 1.47billionattheendofJanuary2025[9]−Long−termdebtwas3.349 billion, with cash flow from operating activities increasing to 652millionfrom431 million in the previous quarter [10] Guidance - For Q3 fiscal 2025, management expects revenues between 1.645billionand1.675 billion, indicating a rise of 4.2% to 6.1% on a reported basis [11] - Fiscal 2025 revenue guidance was revised to 6.73billionto6.81 billion, implying an increase of 3.4% to 4.6% on a reported basis [11] - Non-GAAP earnings per share guidance for fiscal 2025 remains at 5.54to5.61 [12]